These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31130321)

  • 1. Alpelisib plus fulvestrant for PIK3CA-mutated breast cancer.
    Stirrups R
    Lancet Oncol; 2019 Jul; 20(7):e347. PubMed ID: 31130321
    [No Abstract]   [Full Text] [Related]  

  • 2. Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
    Hoste G; Slembrouck L; Jongen L; Punie K; Matton T; Vander Borght S; Vanden Bempt I; Menten J; Wildiers H; Floris G; Arteaga C; Neven P
    Clin Drug Investig; 2018 Nov; 38(11):1071-1075. PubMed ID: 30187361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
    Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
    JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
    Narayan P; Prowell TM; Gao JJ; Fernandes LL; Li E; Jiang X; Qiu J; Fan J; Song P; Yu J; Zhang X; King-Kallimanis BL; Chen W; Ricks TK; Gong Y; Wang X; Windsor K; Rhieu SY; Geiser G; Banerjee A; Chen X; Reyes Turcu F; Chatterjee DK; Pathak A; Seidman J; Ghosh S; Philip R; Goldberg KB; Kluetz PG; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
    Clin Cancer Res; 2021 Apr; 27(7):1842-1849. PubMed ID: 33168657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpelisib for
    André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
    N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
    Rugo HS; Lerebours F; Ciruelos E; Drullinsky P; Ruiz-Borrego M; Neven P; Park YH; Prat A; Bachelot T; Juric D; Turner N; Sophos N; Zarate JP; Arce C; Shen YM; Turner S; Kanakamedala H; Hsu WC; Chia S
    Lancet Oncol; 2021 Apr; 22(4):489-498. PubMed ID: 33794206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpelisib: First Global Approval.
    Markham A
    Drugs; 2019 Jul; 79(11):1249-1253. PubMed ID: 31256368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-Reported Outcomes in Patients With
    Ciruelos EM; Rugo HS; Mayer IA; Levy C; Forget F; Delgado Mingorance JI; Safra T; Masuda N; Park YH; Juric D; Conte P; Campone M; Loibl S; Iwata H; Zhou X; Park J; Ridolfi A; Lorenzo I; André F
    J Clin Oncol; 2021 Jun; 39(18):2005-2015. PubMed ID: 33780274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
    André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
    Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpelisib to treat breast cancer.
    Copur MS
    Drugs Today (Barc); 2020 Jun; 56(6):357-363. PubMed ID: 32525134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
    Jacobson A
    Oncologist; 2022 Mar; 27(Suppl 1):S13-S14. PubMed ID: 35348782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?
    Wu W; Lin H; Cai J; Sun H; Liu J; Hu C; Wei X
    Clin Drug Investig; 2023 Dec; 43(12):939-948. PubMed ID: 37975961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+
    Pérez-Fidalgo JA; Criscitiello C; Carrasco E; Regan MM; Di Leo A; Ribi K; Adam V; Bedard PL
    Future Oncol; 2022 Jun; 18(19):2339-2349. PubMed ID: 35465733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for Long-Term Disease Control with Alpelisib Plus Fulvestrant Spans Patient Subgroups in HR+ PIK3CA-Mutated Advanced Breast Cancer.
    Oncologist; 2021 Jul; 26 Suppl 3(Suppl 3):S11-S12. PubMed ID: 34173298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
    Bertho M; Patsouris A; Augereau P; Robert M; Frenel JS; Blonz C; Campone M
    Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):139-152. PubMed ID: 33213227
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
    Dickler MN; Saura C; Richards DA; Krop IE; Cervantes A; Bedard PL; Patel MR; Pusztai L; Oliveira M; Cardenas AK; Cui N; Wilson TR; Stout TJ; Wei MC; Hsu JY; Baselga J
    Clin Cancer Res; 2018 Sep; 24(18):4380-4387. PubMed ID: 29793946
    [No Abstract]   [Full Text] [Related]  

  • 17. [New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].
    Corbaux P; Sabatier R
    Bull Cancer; 2020 Oct; 107(10):959-960. PubMed ID: 32977934
    [No Abstract]   [Full Text] [Related]  

  • 18. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
    Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
    J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpelisib for the treatment of
    Leenhardt F; Alexandre M; Jacot W
    Expert Opin Pharmacother; 2021 Apr; 22(6):667-675. PubMed ID: 33622114
    [No Abstract]   [Full Text] [Related]  

  • 20. Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
    Wang S; Liu M; Lian S; Liu N; Zhang G; Zhao Q; Zhang Y; Jian L
    Biomed Res Int; 2020; 2020():7451576. PubMed ID: 33376736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.